The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA‐HF study

BACKGROUND: Canagliflozin reduces hospitalizations for heart failure (HF) in type 2 diabetes mellitus (T2DM). Its effect on cardiorespiratory fitness and cardiac function in patients with established HF with reduced ejection fraction (HFrEF) is unknown. METHODS: We conducted a double‐blind randomize...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Diabetes Metab Res Rev
Autors principals: Carbone, Salvatore, Billingsley, Hayley E., Canada, Justin M., Bressi, Edoardo, Rotelli, Brando, Kadariya, Dinesh, Dixon, Dave L., Markley, Roshanak, Trankle, Cory R., Cooke, Richard, Rao, Krishnasree, B. Shah, Keyur, Medina de Chazal, Horacio, Chiabrando, Juan Guido, Vecchié, Alessandra, Dell, Megan, L. Mihalick, Virginia, Bogaev, Roberta, Hart, Linda, Van Tassell, Benjamin W., Arena, Ross, Celi, Francesco S., Abbate, Antonio
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2020
Matèries:
Research Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7685099/
https://ncbi.nlm.nih.gov/pubmed/32415802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/dmrr.3335
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars